GlaxoSmithKline plc’s (GSK) “Hold” Rating Reiterated at Deutsche Bank AG

GlaxoSmithKline plc (LON:GSK)‘s stock had its “hold” rating reaffirmed by Deutsche Bank AG in a research note issued on Wednesday. They currently have a GBX 1,610 ($21.17) price objective on the stock. Deutsche Bank AG’s target price suggests a potential upside of 6.24% from the company’s previous close.

Other equities analysts have also issued reports about the company. Jefferies Group LLC restated a “buy” rating and issued a GBX 1,900 ($24.98) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Bryan, Garnier & Co restated a “buy” rating and issued a GBX 1,750 ($23.01) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 20th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a GBX 1,900 ($24.98) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 20th. Liberum Capital restated a “buy” rating and issued a GBX 1,900 ($24.98) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, June 14th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 1,885 ($24.78) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, July 26th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,689.48 ($22.21).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1515.50 on Wednesday. The stock’s 50 day moving average price is GBX 1,499.71 and its 200 day moving average price is GBX 1,587.03. GlaxoSmithKline plc has a 12-month low of GBX 1,444.00 and a 12-month high of GBX 1,724.50. The firm’s market capitalization is GBX 74.08 billion.

COPYRIGHT VIOLATION NOTICE: This article was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/10/11/glaxosmithkline-plcs-gsk-hold-rating-reiterated-at-deutsche-bank-ag.html.

In other GlaxoSmithKline plc news, insider Patrick Vallance acquired 861 shares of the company’s stock in a transaction on Friday, July 14th. The stock was acquired at an average price of GBX 1,618 ($21.27) per share, for a total transaction of £

Other equities analysts have also issued reports about the company. Jefferies Group LLC restated a “buy” rating and issued a GBX 1,900 ($24.98) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 13th. Bryan, Garnier & Co restated a “buy” rating and issued a GBX 1,750 ($23.01) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 20th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a GBX 1,900 ($24.98) target price on shares of GlaxoSmithKline plc in a research note on Thursday, July 20th. Liberum Capital restated a “buy” rating and issued a GBX 1,900 ($24.98) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, June 14th. Finally, Berenberg Bank restated a “buy” rating and issued a GBX 1,885 ($24.78) target price on shares of GlaxoSmithKline plc in a research note on Wednesday, July 26th. Four equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and seven have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of GBX 1,689.48 ($22.21).

Shares of GlaxoSmithKline plc (LON:GSK) opened at 1515.50 on Wednesday. The stock’s 50 day moving average price is GBX 1,499.71 and its 200 day moving average price is GBX 1,587.03. GlaxoSmithKline plc has a 12-month low of GBX 1,444.00 and a 12-month high of GBX 1,724.50. The firm’s market capitalization is GBX 74.08 billion.

COPYRIGHT VIOLATION NOTICE: This article was reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://ledgergazette.com/2017/10/11/glaxosmithkline-plcs-gsk-hold-rating-reiterated-at-deutsche-bank-ag.html.

In other GlaxoSmithKline plc news, insider Patrick Vallance acquired 861 shares of the company’s stock in a transaction on Friday, July 14th. The stock was acquired at an average price of GBX 1,618 ($21.27) per share, for a total transaction of £13,930.98 ($18,315.78). Also, insider Manvinder Singh Banga acquired 2,267 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was acquired at an average price of GBX 1,599 ($21.02) per share, with a total value of £36,249.33 ($47,658.86). In the last quarter, insiders acquired 3,144 shares of company stock valued at $5,042,191.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply